HIT Consultant – Read More
What You Should Know
- The Launch: GoodRx has announced it is now offering Wegovy HD—Novo Nordisk’s newly introduced, higher-dose (7.2 mg) semaglutide injection.
- The Price Point: In a major move for the direct-to-consumer market, the medication is available to eligible self-pay patients at a transparent price of $399 per month. Pricing scales predictably to $798 for a two-month supply and $1,197 for a three-month supply.
- The Clinical Strategy: Wegovy HD serves as an FDA-approved “step-up” option within Novo Nordisk’s portfolio. It allows patients who have plateaued on standard doses to achieve greater weight-loss benefits without having to switch brands or care pathways.
A New Step-Up in the Wegovy Portfolio
Wegovy® HD (semaglutide) 7.2 mg injection provides a new FDA-approved option within the existing Wegovy treatment arc. This higher-dose strength is designed for eligible patients who may benefit from an additional step-up in their clinical journey without the need to switch brands or care pathways.
The transparent pricing through GoodRx is designed to scale with quantity, providing consumers with clear cost expectations:
- One-month supply: $399.
- Two-month supply: $798.
- Three-month supply: $1,197.
Operationalizing Access at Scale
As manufacturers increasingly manage GLP-1s as long-term portfolios, platforms like GoodRx are becoming essential for connecting patients to innovation. By surfacing upfront pricing and linking it to a network of pharmacies nationwide, GoodRx simplifies the process of obtaining these medications outside of traditional insurance channels.
“Wegovy HD is a strong example of how manufacturers are expanding options to support patients at different stages of treatment,” said Wendy Barnes, President & CEO at GoodRx. “GoodRx is proud to help translate that innovation into real-world access.”
Integrated Care Through “GoodRx for Weight Loss”
To streamline the patient experience, the company’s GoodRx for Weight Loss subscription service provides a connected care pathway. Through this platform, consumers can:
- Meet with licensed healthcare providers.
- Complete a clinical eligibility assessment.
- Obtain a prescription for FDA-approved GLP-1 treatments when appropriate.
This initiative reinforces GoodRx’s role in the healthcare ecosystem, having saved Americans over $100 billion on medication costs since 2011.
